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Intralesional administration of cultured dendritic cells
(DCs) engineered to produce IL-12 by in vitro infection with
recombinant adenovirus frequently displays eradicating effi-
cacy against established subcutaneous tumors derived from
the CT26 murine colon carcinoma cell line. The elicited
response is mainly mediated by cytolitic T lymphocytes. In
order to search for strategies that would enhance the efficacy
of the therapeutic procedure against less immunogenic tu-
mors, we moved onto malignancies derived from the inocu-
lation of MC38 colon cancer cells that are less prone to
undergo complete regression upon a single intratumoral in-
jection of IL-12-secreting DCs. In this model, we found that
repeated injections of such DCs, as opposed to a single injec-
tion, achieved better efficacy against both the injected and a
distantly implanted tumor; that the use of semiallogeneic
DCs that are mismatched in one MHC haplotype with the
tumor host showed slightly better efficacy; and that the com-
bination of this treatment with systemic injections of immu-
nostimulatory anti-CD137 (4-1BB) monoclonal antibody
achieved potent combined effects that correlated with the
antitumor immune response measured in IFN- ELISPOT
assays. The elicited systemic immune response eradicates
concomitant untreated lesions in most cases. Curative effi-
cacy was also found against some tumors established for 2
weeks when these strategies were used in combination.
These are preclinical pieces of evidence to be considered in
order to enhance the therapeutic benefit of a strategy that is
currently being tested in clinical trials. Supplementary Mate-
rial for this aricle can be found on the International Journal of
Cancer website at http://www.interscience.wiley.com/jpages/
0020-7136/Suppmat/index.html.
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Dendritic cells are the physiologic initiators of cellular immune
responses.1 Their properties as professional antigen-presenting
cells2 have been exploited to elicit prophylactic and therapeutic
immunity against experimental tumors3 and are being tested in
clinical trials against a wide array of human malignances.4,5 Most
strategies include a technique of isolation or in vitro differentiation
of dendritic cells (DCs), plus an in vitro manipulation of such DCs
to introduce tumor antigens into their antigen-presenting pathways.
Eventually, these DCs are given to mice or patients by different
routes to elicit antitumor immune responses. Preclinical and clin-
ical research is still trying to define the best subtype of DCs, the
best source of antigen and the best route and schedule of admin-
istration. Antigens can be given to DCs as chemically defined
proteins3,6 or by transfecting the genes that encode for them.7
Alternatively, relevant antigens can be given to DCs as complex
mixtures that contain many defined as well as undefined antigenic
sequences:8 tumor lysate,9 total tumor RNA,10 tumor-derived exo-
somes,11 apoptotic malignant cells.12 We favor the second alter-
native because it would potentially target many antigenic se-
quences, making antigen loss variants less likely to evade the
response, and because it resembles the natural mechanisms of
crosspriming.8 It has been observed that repetitive doses of anti-
gen-pulsed DCs boost the immune response and reach higher
efficacy than a single dose.13
DCs injected inside malignant tissue can uptake tumor antigens
and subsequently migrate to lymphoid organs.14 This simple pro-
cedure induces immunity against a later challenge with the same
tumor, but is inefficient to treat established tumors.15 On the other
hand, if DCs are transfected with expression cassettes for IL-
12,14,16 CD40L17 or IL-7,18 they induce tumor rejection in the
transplanted tumors with unprecedented efficacy.19 IL-12 is a
heterodimeric cytokine that has been transfected into DCs by
means of recombinant retrovirus14 and adenovirus.16 Levels of
expression are superior when adenovirus are used and they in-
crease proportionally with higher multiplicity of infections
(MOIs).16,20 Adenoviral vectors are currently considered the best
choice for DC transfection in order to introduce genes encoding
either antigens or cytokines.19 IL-12-transfected DCs, when arti-
ficially delivered inside tumors, ignite complex mechanisms that
ultimately elicit a cytotoxic T-lymphocyte (CTL)-mediated effec-
tor immune response.16 Apart from CD8 T cells, we have pre-
viously demonstrated a role for CD4 T and natural killer (NK)
cells,21 which are stimulated at early time points by IL-12 to
produce interferon (IFN)-.22 IFN- is a cytokine induced by
IL-12 in an antigen-independent fashion,23 which is critical for the
observed antitumor effects upon intratumoral injection of IL-12-
transfected DCs.22 In fact, IL-12 administered as a recombinant
protein has shown remarkable properties as an antitumor agent and
the endogenous function of this cytokine is necessary in many
experimentally successful immunotherapeutic approaches.24–28
Unfortunately, clinical development of systemic recombinant
IL-12 was slowed by undue IFN--dependent toxicity that resulted
from an overestimated maximal tolerated dose. Confinement of
IL-12 production by gene transfer to malignant tissue might lessen
the systemic toxicity.23,24 In the case of IL-12-transfected DCs,
there exist autocrine effects of IL-12 on DCs that induce DC
functional changes, which differentiate DCs into better T-cell
activators.29 It has been observed that intratumorally injected DCs
migrate to lymph nodes while presenting antigens taken up in
tumor tissue and secreting important amounts of IL-12.14,22,30
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Alloantigens have been used to enhance immune responses
against tumor antigens by means of eliciting potent T-helper
activity.31 The advantage is that the T-cell repertoire is enriched in
naive T cells that recognize allogeneic major histocompatibility
complex (MHC) molecules due to thymic positive selection. Hy-
bridomas of autologous tumor cells fused with fully allogeneic
DCs have been shown to be effective against human renal carci-
nomas.32 In that setting, the malignant cell provides MHC-I mol-
ecules that present tumor antigens and the DC provides costimu-
latory activity and allogeneic helper antigens. Fully allogeneic
DCs transfected to produce IL-12 do not induce tumor regression
when injected intratumorally due to the lack of compatible anti-
gen-presenting molecules.16 Here we tried IL-12-transfected DCs
from semiallogeneic F1 mice that result from breeding the tumor-
bearing strain with a different pure strain, in such a way that they
share one MHC (H-2) haplotype but are mismatched in the other
haplotype.
Agonistic anti-CD137 (anti-4-1BB) antibodies have been de-
scribed to induce curative immune responses against several trans-
planted tumors.33–35 CD137 is a surface antigen that is expressed
on both activated T and NK cells.36 It has been recently described
that treatment with anti-CD137 monoclonal antibody exerts syn-
ergistic effects with procedures of vaccination using peptides in
such a way that this treatment breaks the status of tumor antigen
ignorance.34 The detailed mechanism of action of anti-CD137
monoclonal antibody is not clear and might involve direct effects
on T cells, but also on DCs as recently described.37 Importantly,
systemic treatment with anti-CD137 monoclonal antibody syner-
gizes with gene transfer of IL-12 into tumor cells, achieving
excellent therapeutic activity against murine tumors.38–40
In this study, we have increased the potency of the therapeutic
effects elicited by intratumorally injected IL-12-secreting DCs
against experimental colorectal cancer by several approaches, in-
cluding repetition of doses, use of semiallogeneic DCs expressing
helper alloantigens (from a mismatched H-2 haplotype), and/or
combination with immunostimulatory anti-CD137 monoclonal an-
tibodies.
MATERIAL AND METHODS
Mice
BALB/c, C57BL/6 and CB6F1 mice (result from the cross of
these strains: BALB/c  C57BL/6) were obtained from Harlan
(Barcelona, Spain) and used between 7 and 14 weeks of age. Green
fluorescent protein (GFP) transgenic mice41 in C57BL/6 back-
ground were a generous gift from M. Okabe (Genome Information
Research Center, Osaka University, Osaka, Japan) and were bred
in our animal facility. All experiments were performed in agree-
ment with our institution’s Committee on Animal Research and
Ethics guidelines (study approval number 003/02).
DC culture and phenotype
Bone marrow-derived DCs were obtained as previously de-
scribed.16 Briefly, bone marrows were flushed out from the long
bones of the rear limbs of mice and erythrocytes were lysed with
a hypotonic buffer. Granulocytes, T and B lymphocytes were
depleted by treatment with a cocktail containing anti-CD4, anti-
CD8, anti-Gr-1 and anti-B220 monoclonal antibodies (Pharmin-
gen, San Diego, CA) and rabbit complement (Sigma, Madrid,
Spain). Cells were cultured for 7 days in 12-well plates (TPP,
Trasadingen, Switzerland) at 106 cells/ml in RPMI-1640 medium
(Gibco, Basel, Switzerland) supplemented with 100 U/ml penicil-
lin (Life Technologies, Bethesda, MD), 100 g/ml streptomycin, 2
mM L-glutamine, 10% fetal bovine serum (FBS; Gibco), 20 ng/ml
rmIL-4 (PeproTech, London, U.K.) and 20 ng/ml rmGM-CSF
(PeproTech). At days 3 and 5 of culture, nonadherent cells were
removed and fresh medium with cytokines was added. On day 7,
cells in suspension and loosely adherent cells were collected.
Phenotype of DCs was assessed by flow cytometry (FACScalibur,
Becton Dickinson, San Jose, CA) upon staining with FITC-con-
jugated monoclonal antibody (mAb) against CD80, CD86, CD11c,
CD40, CD14, H-2Kd, H-2Kb, I-Ad and I-Ab (Supplementary Ma-
terial can be found on the International Journal of Cancer website
at http://www.interscience.wiley.com/jpages/0020-7136/suppmat/
index/html) for 30 min at 4°C (all antibodies were also from
Pharmingen). Nonreactive fluorochrome-tagged rat monoclonal
antibody was used as control.
Adenoviruses encoding murine IL-12 and -galactosidase genes
and DC transfection
Defective recombinant adenoviruses AdCMVmIL-12 and
AdCMVlacZ were constructed and titered as described.42,43 DCs
were harvested at day 7 of culture, plated at 107 cells/ml in
serum-free medium and infected for 1 hr with the indicated ade-
novirus at an MOI of 3,000. After infection, RPMI 10% FBS was
added to the wells and cells were subsequently incubated at 37°C
for 20 hr. After incubation, adenovirus-transfected DCs were har-
vested, washed 3 times with HBSS and resuspended into a cell
density of 5  105 DCs in 60 l of HBSS. For dendritic cell
labeling, we incubated DCs with the fluorescent dye PKH2 (Sig-
ma-Aldrich). To detect migrated DCs, a conventional optical mi-
croscope (Nikon) equipped with a UV light source was used to
observe frozen inguinal lymph node sections. Cell suspensions of
similar lymph nodes were examined by FACS and fluorescent cells
were quantified.
Production and purification of mAb
A rat IgG2a against murine CD137, 2A, was generated as
previously described.34 The protein in the culture supernatants was
purified using a HiTrap protein G–sepharose column (Amersham
Pharmacia Biotech, Piscataway, NJ) and dialyzed in LPS-free
PBS. Endotoxin levels were undetectable.34
Tumor cell lines and tumor inoculation
CT26 and MC38 are colon adenocarcinoma cell lines of
BALB/c and C57BL/6 origin, respectively.16 Cell lines were main-
tained at 37°C in 5% CO2 and were grown in Dulbecco’s modified
Eagle’s medium (DMEM) with 2 mM L-glutamine, 100 U/ml
streptomycin, 100 g/ml penicillin and supplemented with 10%
heat-inactivated fetal bovine serum. All cell culture reagents were
from Gibco.
In order to assess the efficacy of treatments on tumor-bearing
mice in vivo, 5  105 CT26 cells in 100 l HBSS (Gibco) were
injected subcutaneously in the right flank or in both flanks of
BALB/c mice with a 28 G syringe. Similarly, 5  105 MC38 cells
were injected into C57BL/6 mice. Mice were treated with DC-
AdCMVIL-12, DC-AdCMVlacZ, or nontransfected DCs by intra-
tumoral injection of 5  105 DCs in 60 l of HBSS using a 28 G
syringe. Anti-CD137 antibody was intraperitoneally injected with
a similar syringe. Tumor growth was measured weekly using a
Vernier precision caliper.
ELISPOT assays
Enzyme-linked immunospot (ELISPOT) assays for the detec-
tion of tumor-specific interferon--producing spleen cells were
performed as described.44,45 Briefly, 96-well nitrocellulose plates
(Multiscreen HA, Millipore, Bedford, MA) were coated with an-
timouse IFN- mAb R4 (Pharmingen). After overnight incubation
at room temperature, wells were washed with PBS. Remaining
protein binding sites were blocked with 10% FBS DMEM. CT26
cells were incubated with mitomycin C (100 g/ml) for 1 hr at
37°C, washed, counted and diluted in complete DMEM supple-
mented with IL-2 (30 IU/ml; Chiron, Emeryville, CA). Spleen
mononuclear cells from treated and control mice were harvested at
day 47 after tumor inoculation. Serial dilutions were prepared in
complete DMEM with IL-2 and exposed to 104 mitomycin C-
treated CT26 cells. After 24-hr incubation at 37°C, plates were
washed with PBS and PBS/Tween 20 (PBS/T; Sigma). A biotin-
ylated antimouse IFN-mAb XMG1.2 (Pharmingen) was added in
PBS/T and plates were incubated for 3 hr at room temperature. The
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unbound antibodies were removed by washing 6 times with
PBS/T. A peroxidase-labeled streptavidin (Kirkegaard and Perry
Laboratories, Gaithersburg, MD) was added and plates were incu-
bated for 1 hr at room temperature. After incubation, plates were
washed with PBS and PBS/T and developed by adding 100 l/well
of peroxidase substrate: 50 mM Tris–HCl at pH 7.5 containing 1
mg/ml of DAB (Sigma-Aldrich) and 0.5 l/ml of 30% hydrogen
peroxide (Sigma). Plates were incubated at room temperature for
10–15 min until spots became microscopically visible. Spots were
doubly counted in each well under optical magnification and
results were expressed as spots/106 spleen mononuclear cells.
Statistical analysis
Fisher’s exact and Mann-Whitney tests were computer-assisted
with SPSS 9.0 software (SPSS, Chicago, IL).
RESULTS
Intratumoral injection of AdCMVIL-12-transduced DCs displays
systemic effects against disseminated colon cancer in mice
We have previously reported that a single injection of 105 bone
marrow-derived dendritic cells into tumor nodules (5–7 mm in
diameter) derived from the subcutaneous injection of CT26 cells
was curative in 60–80% of cases if DCs had been adenovirally
transduced to express IL-12.16 In Figure 1, we show an experiment
in which BALB/c mice were subcutaneously inoculated with 5 
105 CT26 cells in both flanks. In 8 days, such mice developed
tumors ranging from 5 to 9 mm that were well vascularized (not
shown). On day 8, the right tumor nodule was injected with 5 
105 autologous bone marrow-derived DCs that had been trans-
fected with AdCMVIL-12 (a defective recombinant adenovirus
that encodes for both chains of murine IL-12). Treated nodules
experienced shrinkage and complete regression in 7 out of 8 cases
within 1–2 weeks after treatment. Importantly, the lesions growing
in the opposite, untreated flank also underwent complete regres-
sion in 6 out of 8 cases. Regressions in the contralateral tumor took
place with a delay of 1–2 weeks when compared to the treated
tumor, suggesting different kinetics of the rejection process. It is of
note that one of the tumors, which eventually killed one of the
mice, experienced a transient partial regression (Fig. 1). By con-
trast, mice that were treated with identically derived DCs, but
transfected with a control recombinant adenovirus (AdCMVlacZ,
which encodes for -galactosidase) only showed a transient de-
crease in tumor growth in a minority of cases. Cured mice were
followed up for 5 months without signs of disease or relapse. In a
different set of experiments performed in 6 mice bearing CT26
solitary tumor nodules in the middle lobe of the liver (4–7 mm of
mean diameter), the intratumor injection induced complete regres-
sions in 4 out of 6 cases, while all tumors in the control group
rapidly progressed (data not shown). These experiments imply that
this treatment strategy might be beneficial for patients with ma-
lignant disseminated disease nested into the liver.
Semiallogeneic origin and dose repetition enhance antitumor
efficacy of IL-12-secreting DCs
In order to investigate new approaches to improve the effect of
our treatment, a more challenging tumor model consisting in the
subcutaneous injection of MC38 colon cancer cells in syngeneic
C57BL/6 mice was necessary. Such a model shows markedly less
intrinsic immunogenicity than CT26. In order to substantiate in a
direct comparison setting that MC38-derived tumors were less
susceptible to immunotherapy with IL-12-transduced DCs than
CT26-derived tumors, we performed experiments in F1(BALB/
c C57BL/6) mice. Both CT26 and MC38 cells grafted as rapidly
progressive tumors in these hybrid CB6F1 mice. After injection of
IL-12-transduced autologous DCs (from syngeneic F1 mice),
CT26 tumors were completely rejected in more cases (5/6 vs. 2/6
tumor-free mice at day 63) and with clearly faster kinetics than
MC38 tumors (not shown).
In Figure 2(a), we show that treatment of MC38 tumors with a
single injection of 5  105 autologous DCs transfected to produce
FIGURE 1 – Intratumoral injection of Ad-
CMVIL-12-transduced DCs display sys-
temic effects against disseminated CT26-
derived colon cancer in mice. Tumor size
follow-up of BALB/c mice (8 per group)
bearing 2 subcutaneous tumor nodules de-
rived from the injection of 5  105 CT26
cells 8 days prior to injection of the right-
flank nodule with 5  105 DCs transfected
with AdCMVIL-12 or AdCMVlacZ as a
control. Sizes (mean diameter) of injected
and contralateral noninjected nodule are
given. Fraction of tumor-free surviving
mice is given inside each graph. Superiority
of AdCMVIL-12-transfected DCs was
highly significant (p  0.01 for treated site
and for untreated site) according to Fisher’s
exact test.
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IL-12 failed to induce tumor rejection and only one mice experi-
enced tumor shrinkage, but even that particular tumor eventually
relapsed. In spite of this fact, it is of note that there was a
significant decrease in the rate of growth of most tumors if com-
pared to control groups.
Since alloantigens could help the immune response to tumor
antigens, we tried DCs derived from CB6F1 (BALB/c female 
C57BL/6 male) mice that express the H-2d haplotype encoding for
major histocompatibility alloantigens and also for autologous H-2b
antigen-presenting molecules. A single injection of 5  105 semi-
allogeneic DCs achieved 2 out of 6 complete regressions and one
mouse showed impalpable tumor at one time point, although it
later experienced a relapse. Mice treated either with autologous or
semiallogeneic DCs without IL-12 transfection showed fast pro-
gressive and lethal tumor growth similar to that observed in
untreated mice (Fig. 2a).
To test if we could improve our results in the MC38 model with
repetition of DC doses, we set up a bilateral model of 2 simulta-
neously induced tumor nodules. Mice injected in both flanks with
5  105 MC38 cells developed tumors of 3–7 mm in 8 days. On
that day (day 8) and on day 10, mice received 2 doses of 5  105
bone marrow-derived DCs each, from either autologous or semi-
allogeneic origin. The directly treated tumor site in the case of
autologous DCs completely regressed in 7 out of 12 cases. Al-
though only 1 out of 12 contralateral nodules experienced com-
plete regression, a 3-week stabilization of growth was observed in
at least 6 other tumor nodules (Fig. 2b). Using 2 doses of IL-12-
transduced F1-DC, 9 out of 11 directly injected tumors regressed
while 3 out of 11 did so in the untreated side (Fig. 2b). Pooling
data with an identically performed experiment, statistically signif-
icant differences between F1DC-IL12 and autologous DC-IL-12
groups were found (Fisher’s exact test, p  0.035; n  17 per
group).
In conclusion, repeated doses and semiallogeneic origin im-
prove the therapeutic efficacy of IL-12-secreting DCs injected into
malignant tissue. Purities of DC preparation of F1 or C57BL/6
mice were similar (see FACS analysis in the Supplementary Ma-
terial on the International Journal of Cancer website at http://
www.interscience.wiley.com/jpages/0020-7136/suppmat/index.html).
Semiallogeneic and autologous DCs migrate similarly to lymph
nodes after intratumoral injection
We had reported in the CT26 model that DCs injected at the
tumor nodule migrated very avidly to draining inguinal lymph
nodes.22 In MC38 model, we also observe a rapid (within 24 hr)
migration of DCs producing IL-12 that had been derived from
C57BL/6 mice expressing GFP as a transgene under the control of
the -actin promoter (Fig. 3a). Interestingly, migrated DCs local-
ize to paracortical T-cell areas of lymph nodes excluding lymphoid
follicles. Infiltration in the nodes of mice treated with DCs intra-
tumorally was similar in the case of autologous and semiallogeneic
DCs, as it can be seen in Figure 3(b) as relative number of
fluorescence cells in lymph nodes. Figure 3(c) shows a represen-
tative FACS analysis of lymph node cell suspensions. These ob-
servations make differential migration an unlikely reason for the
superior effects obtained with semiallogeneic DCs.
Systemic anti-CD137 monoclonal antibody synergizes with
IL-12-producing DCs injected intratumorally
With the help of the model of MC38-derived bilateral tumors,
experiments were performed to investigate if therapeutic efficacy
could be enhanced by combination with anti-CD137 monoclonal
antibody. Such treatment is known to induce tumor eradication in
a number of models and to enhance the efficiency of therapeutic
antitumor vaccination with defined tumor antigens.34
We found that a single dose of autologous bone marrow-derived
DCs on day 8 of bilateral MC38 tumor growth followed by 2
intraperitoneal doses of anti-CD137 on days 9 and 11 achieved
complete bilateral cures in 6 out of 6 mice (Fig. 4).
Injection of anti-CD137 monoclonal antibody without dendritic
cells on the same days accounted for 2 complete bilateral regres-
sions and a case of unilateral regression. In this experiment,
autologous IL-12-transfected DCs plus a regime with irrelevant
control antibody resulted in 2 out of 6 regressions in the treated
site, while contralateral tumors progressed in every case, albeit
slightly slower than in those cases treated with saline buffer. To
rule out potential artifact effects due to production and purification
of mAbs, we tested an irrelevant mAb purified from hybridoma-
conditioned tissue culture medium without observing increases in
antitumor efficacy.
Intratumoral injection of IL-12-secreting DCs plus anti-CD137
antibodies induces more IFN--secreting tumor-responding
lymphocytes
Intratumoral injection of DCs secreting IL-12 is known to
induce both cytotoxic T lymphocytes and Th1-mediated antitumor
responses. To explore the effect of the combination with anti-
CD137 antibodies, we obtained spleen cells from mice with CT26
tumors that had been treated on day 8 of tumor growth with
autologous or semiallogeneic DCs secreting IL-12, along with
anti-CD137 or control antibody. Mice were euthanized at day 47
and the isolated splenocytes were exposed to 104 mitomycin
C-treated CT26 cells in ELISPOT assays and cells producing
IFN- spots in 24 hr were counted.
As it can be seen in Figure 5, treatment with DC-IL-12 plus
anti-CD137 induced more IFN--producing lymphocytes than IL-
12-transfected autologous or semiallogeneic DCs used as single
therapeutic agents. Differences comparing effects of autologous
versus semiallogeneic IL-12-transfected DCs were not statistically
significant in this experiment. ELISPOT analyses were also per-
formed in the MC38 tumor model but a high background of
IFN--producing lymphocytes without tumor antigen stimulation
was found, a feature that is probably peculiar of this tumor model
(data not shown).
Combined strategies to treat 2-week established MC38 bilateral
tumors
Data on repeating doses, semiallogeneic DCs and, above all,
combination with anti-CD137 monoclonal antibody strongly sug-
gested that a combination of these strategies could be efficacious
against tumors established for a longer period of time that are
known to be completely refractory to immunotherapy by IL-12-
secreting intratumoral DCs as a sole treatment (not shown). To
achieve this goal, the bilateral MC38 model was allowed to de-
velop for 13 days without treatment. On this day, mice received
combined regimes of repeated intratumoral IL-12-secreting DCs
along with one intraperitoneal dose of anti-CD137 monoclonal
antibody. We comparatively analyzed autologous (C57BL/6) and
semiallogeneic (F1) origin of DCs. The regimen of DCs consisted
in doses on days 13 and 15. Other groups received a third intra-
FIGURE 2 – (a) Intratumoral injection of IL-12-secreting DCs
achieves slightly better effects if derived from semiallogeneic mice.
Follow-up of tumor size (mean diameter) of C57BL/6 mice implanted
with 5  105 MC38 cells on day 0 and treated on day 7 with 5  105
DCs transfected to produce IL-12 with AdCMVIL-12 or left untrans-
fected. DCs were obtained from syngeneic C57BL/6 mice or from
CB6F1 (BALB/c  C57BL/6) mice as indicated. (b) Dose repetition
and semiallogeneic origin of DCs enhance antitumor efficacy.
C57BL/6 mice were bilaterally injected with 5  105 MC38 cells on
day 0. On days 7 and 10, mice were injected in the right flank tumor
nodule with 5  105 DCs transfected with AdCMVIL-12 or with
saline buffer. The indicated groups were treated with IL-12-transfected
DCs from semiallogeneic or syngeneic origin. Results are the sequen-
tial follow-up of the size of treated and contralateral untreated tumors
with the fraction of tumor-free mice at the end of the experiment.
Pooling data with an identically performed experiment, statistical
differences between F1DC-IL12 and autologous DC-IL-12 groups
were found (Fisher’s exact test, p  0.035; n  17 per group).
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tumor dose of IL-12-secreting DCs on day 16. Antibodies were
given on day 16 to all groups.
In Figure 6, we show that only the administration of 3 doses of
F1 DCs producing IL-12 plus anti-CD137 achieves complete bi-
lateral curative activity in some instances (2 cases out of 8). These
2 mice were tumor-free and well at day 120 after tumor inocula-
tion. Tumor regressions at the DC-injected site were also observed
in mice receiving 2 doses of IL-12-transfected F1 DCs (2 out of 8)
and with 2 or 3 doses of IL-12-transfected autologous DCs (3 and
2 out of 7 cases, respectively). Importantly, a single injection of
anti-CD137 on day 16 was completely ineffective in this setting.
The efficacy observed at inducing tumor regression and the delay
in tumor growth that is shown against these bilateral MC38 tumors
(7–10 mm of diameter) might indicate that these combined re-
gimes could improve the clinical outcome of the corresponding
malignant disease in humans.
DISCUSSION
This study preclinically addresses the issue of improving
intratumoral treatment of colon cancer with DCs transfected to
produce IL-12. Experiments were designed to study new strat-
egies to enhance the local and systemic antitumor response that
is elicited by this treatment. In spite of recent progress in
chemotherapy, novel treatments for disseminated colon cancer
are needed because such condition is almost constantly fa-
tal.46,47
FIGURE 4 – Systemic administration of anti-CD137 monoclonal antibody synergizes with IL-12-producing DCs injected intratumorally.
Follow-up of tumor sizes (mean diameter) of bilateral tumor nodules derived from 5  105 MC38 cells implanted in both flanks on day 0. On
day 7, right tumor nodules were intratumorally treated with autologous DCs transfected to produce IL-12 (in the indicated groups). Two doses
of 100 g of anti-CD137 monoclonal antibody or an irrelevant polyclonal antibody were given at days 9 and 11. Evolution of both the directly
DC-treated tumor and the contralateral tumor were recorded. Fraction of tumor-free surviving mice is given within each graph. Superiority of
DC-IL-12  anti-CD137 over each separate treatment group was statistically significant (p  0.05 according to Fisher’s exact test).
FIGURE 5 – Intratumoral injection of IL-12-secreting DCs plus anti-
CD137 monoclonal antibody induces more IFN--secreting tumor-
responding lymphocytes. BALB/c mice bearing 7-day CT26 tumors
were treated with DCs transfected to produce IL-12 obtained from
autologous or semiallogeneic mice. The indicated groups received a
course of anti-CD137 monoclonal antibody. Mice were followed for
43 days and euthanized to obtain their splenocytes. Results represent
the relative number of splenocytes producing IFN- in response to
mytomicin C-treated CT26 cells in 24-hr ELISPOT assays. Two-tail
Mann-Whitney test showed statistic differences (p  0.05) between
antibody-treated versus untreated groups as indicated.
FIGURE 3 – Similar migration to lymph nodes of autologous and
semiallogeneic IL-12-secreting DCs after intratumoral injection. (a)
Microphotograph (200) under ultraviolet light of the lymph node.
C57BL/6 mice bearing MC38 implanted tumors for 7 days were
injected inside their tumor nodule with IL-12-transfected DCs ob-
tained from the bone marrow of GFP-transgenic mice on C57BL/6
background. Lymphoid follicles (identified in H&E-stained sequential
sections) are indicated as LF. Results are representative of 3 different
experiments observing many microscopic fields. (b) and (c) Bone
marrow-derived DCs obtained from C57BL/6 or CB6F1 mice (as
indicated) were infected with AdCMVIL-12 and 24 hr later were
labeled with the fluorescent dye PKH2. These labeled cells were
injected into MC38 tumors established for 8 days and 24 hr later cell
suspensions from draining lymph nodes were collected and analyzed.
In (b), the relative number of fluorescence cells in lymph nodes is
displayed (n  10 lymph nodes per group); in (c), a representative
FACS analysis from one mouse of each group is shown.
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First, we demonstrated a potent systemic effect of a single dose of
IL-12-producing DCs against the CT26 colon carcinoma. That model
has been mechanistically studied, showing that an effector response of
cytotoxic T lymphocytes accounts for the therapeutic activity.16 Fur-
thermore, it was observed that the function of IFN- early secreted by
T helper and NK cells was critical for the outcome.22
Two studies have shown that migration of labeled DCs from the
subcutaneous tumor to the lymph node takes place in a few
hours.14,22 DCs that carry tumor-derived apoptotic bodies,14 pre-
sumably internalized when transiently residing inside malignant
tissue, are detected in T-cell areas of lymph nodes. Phagocytosis of
such apoptotic bodies,48 or other mechanisms2 are used by DCs to
take up tumor antigens that are subsequently transported to lymph
nodes in order to be presented. The mechanistic picture is not
complete yet and other aspects may arise in the future, such as the
autocrine effect of IL-12 on DCs24,49 and the effects of secreted
IL-12 on tumor stroma.50–52 These latter effects can explain our
findings showing that the directly injected tumor nodules undergo
faster and more frequent rejection than untreated contralateral
tumor sites.
Repeated boosting of an immune response is a very simple
strategy to enhance its efficacy.13 Therefore, we injected IL-12-
producing DCs, repeatedly achieving better results even in the
MC38 bilateral model, which is very inefficiently treated with a
single dose. This has already had important implications, since a
clinical trial consisting in ultrasound-guided intratumoral injection
of DCs adenovirally transfected to produce human IL-12 (AFIL-
12/00/002), ongoing at our institution, involves 3 dose repetitions
for the treatment of liver metastases.19
Another strategy known to enhance immunity to tumors is to
combine specific antigens with potent helper antigens.21 MHC-
encoded alloantigens could be among the best ones due to the
increased frequency of responding T cells in the repertoire, ex-
plained by thymic positive selection.53 Both class II and I alloan-
tigens had been used in antitumor immunization in both rodents
and humans.31
A very simple and clinically feasible strategy to benefit from
these facts is to use DCs sharing with the tumor host one MHC
haplotype to present antigen, but differing in the other haplotype to
provide strong proinflammatory helper antigens. In the clinic, this
could be achieved by using DCs cultured from the patient’s parents
or children or even brothers who share only one HLA haplotype
with the patient.
We report that semiallogeneic dendritic cells are slightly
more efficacious when compared to autologous DCs. Therefore,
clinical evaluation of haploidentical allogeneic DCs transfected
to produce IL-12 seems to be a reasonable alternative. This idea
has practical implications because the clinical status of some
cancer patients might difficult leukocyte-apheresis and suffi-
cient yields of DCs from monocytes. Therefore, donation of
surrogate DCs by haploidentical relatives might be a convenient
alternative even if the DCs with an MHC discrepancy in one
MHC haplotype were only as efficacious as the autologous
counterparts.
Among the best newly described immunotherapy treatments, the
use of anti-CD137 monoclonal antibodies stands out.33 mAbs that
given systemically bind CD137 (4-1BB) on activated T54,55 and
NK cells36,56 as well as on certain DCs,37 are capable stimulate
ongoing CTL responses toward weak tumor34 or viral antigens.57
Indeed, it synergizes with peptide immunization with CTL-recog-
nized epitopes34 or with adoptive T-cell therapy.58,59
FIGURE 6 – Combined strategies to treat 2-week established MC38 tumors. C57BL/6 mice were injected subcutaneously in both flanks and left
for 13 days. On days 13 and 15, mice received 2 doses of IL-12-transfected DCs of the indicated origin. The indicated groups received a third
dose of IL-12-transfected DCs on day 16. In the indicated graphs, mice received 100 g of anti-CD137 monoclonal antibody given
intraperitoneally on day 16. Individual sizes (mean diameter) of the nodule directly treated with DCs and the contralateral tumors are shown.
The fraction of tumors regressing in each group is given.
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Given the amplification properties of anti-CD137 antibodies on
the CTL immune response,60 we tested its combination with in-
tratumoral injection of IL-12-producing DCs. Synergistic effects
of combined treatment were curative in every mouse bearing
1-week established MC38 bilateral tumors. Such findings, together
with its partial efficacy on 2-week established bilateral models
derived from the same experimental colon cancer, are very en-
couraging for subsequent clinical development. An effort to pro-
duce GMP-manufactured humanized anti-CD137 monoclonal an-
tibody to be used in the clinic is ongoing. Its combination with
intratumorally injected DCs should be tested soon for safety and
efficacy in phase I clinical trials. However, caution must be kept
since efficacy in tumor mouse models does not mean that similar
effects are to be expected in the clinic. For instance, tumor burdens
measured in volume are dramatically different in rodents and
human beings.
In our hands, anti-CD137 antibodies enhance the frequency of
antitumor-responding IFN--producing T lymphocytes. This im-
plies that the mechanism of action of anti-CD137 mAbs in this
therapeutic synergy could be an increase of the amount of tumor-
reactive T cells. Such an effect could result from a greater T-cell
clonal expansion, longer survival as well as recruitment of more
T-cell clones into the immune response, such as those that recog-
nize subdominant antigenic determinants (epitope broadening), as
it has been observed in a viral infection model.57
It is worth commenting that we have not observed any signifi-
cant autoimmunity-related conditions in mice treated intratumor-
ally with DC-IL12, anti-4-1BB, or the corresponding combined
treatment. Follow-up for 1 year disclosed no changes in body
weight, alertness or general wellbeing. Only some cases of alope-
cia were noted in old cured mice but could not be related to the
treatment since this is a condition frequently affecting C57BL/6
mice at an old age. Therefore, although DCs could be presenting
endogenous normal sequences, serious autoimmunity did not take
place.
As a whole, these new findings on the treatment of experimental
colon cancer with DCs transfected ex vivo with adenovirus to
produce IL-12 are interesting in terms of further increases of
efficacy and have implications for future clinical trials involving
combination of various immunotherapy strategies.
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